RHOB and neoplasm: In these conditions, erlotinib treatment induced a strong anti‐tumoral response in EGFRL858R/Rhob−/− and EGFRL858R/Rhob+/− mice, whereas no significant tumor shrinkage was observed in EGFRL858R/Rhob+/+ mice (Fig 2A).